Literature DB >> 34228199

Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques.

Won Hyeong Im1, Ji Soo Song2,3,4, Weon Jang5,6,7.   

Abstract

Liver fibrosis features excessive protein accumulation in the liver interstitial space resulting from repeated tissue injury due to chronic liver disease. Liver fibrosis eventually proceeds to cirrhosis and associated complications. So, early diagnosis and staging of liver fibrosis are of vital importance for clinical treatment. Liver biopsy remains the gold standard for the diagnosing and staging of fibrosis, but it is suboptimal due to various limitations. Recently, efforts have been made to migrate toward noninvasive techniques for assessing liver fibrosis. CT is relatively easy to perform, relatively standardized for different scanners, and does not require additional hardware in liver fibrosis staging. MRI is frequently performed to characterize indeterminate liver lesions. Because it does not use ionizing radiation and features high image contrast, its role has increased in the staging of liver fibrosis. More recently, several studies on liver fibrosis staging using deep learning algorithms in CT or MRI have been proposed and have shown meaningful results. In this review, we summarize the basic concept, diagnostic performance, and advantages and limitations of each technique to noninvasively stage liver fibrosis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Deep learning; Fibrosis; Liver cirrhosis; Magnetic resonance imaging; Quantitative imaging

Mesh:

Year:  2021        PMID: 34228199     DOI: 10.1007/s00261-021-03181-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  79 in total

Review 1.  Spectrum of imaging findings of the liver in end-stage cirrhosis: part I, gross morphology and diffuse abnormalities.

Authors:  G D Dodd; R L Baron; J H Oliver; M P Federle
Journal:  AJR Am J Roentgenol       Date:  1999-10       Impact factor: 3.959

2.  Expanded gallbladder fossa: simple MR imaging sign of cirrhosis.

Authors:  K Ito; D G Mitchell; T Gabata; S M Hussain
Journal:  Radiology       Date:  1999-06       Impact factor: 11.105

3.  Liver biopsy: the best, not the gold standard.

Authors:  Pierre Bedossa; Fabrice Carrat
Journal:  J Hepatol       Date:  2008-11-06       Impact factor: 25.083

Review 4.  Multidetector Computed Tomography for Retrospective, Noninvasive Staging of Liver Fibrosis.

Authors:  Meghan G Lubner; Perry J Pickhardt
Journal:  Gastroenterol Clin North Am       Date:  2018-07-07       Impact factor: 3.806

Review 5.  Burden of liver diseases in the world.

Authors:  Sumeet K Asrani; Harshad Devarbhavi; John Eaton; Patrick S Kamath
Journal:  J Hepatol       Date:  2018-09-26       Impact factor: 25.083

6.  Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis.

Authors:  Andrew Dennis Smith; Kristin K Porter; Asser Abou Elkassem; Rupan Sanyal; Mark E Lockhart
Journal:  AJR Am J Roentgenol       Date:  2019-04-11       Impact factor: 3.959

Review 7.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

8.  Double contrast-enhanced MRI of viral hepatitis-induced cirrhosis: correlation of gross morphological signs with hepatic fibrosis.

Authors:  J S Yu; J H Shim; J J Chung; J H Kim; K W Kim
Journal:  Br J Radiol       Date:  2009-06-08       Impact factor: 3.039

Review 9.  Non-invasive diagnosis of liver fibrosis: A review of current imaging modalities.

Authors:  Ling Wu; Yue Shen; Feng Li
Journal:  Gastroenterol Hepatol       Date:  2020-02-20       Impact factor: 2.102

Review 10.  Liver fibrosis imaging: A clinical review of ultrasound and magnetic resonance elastography.

Authors:  Yingzhen N Zhang; Kathryn J Fowler; Arinc Ozturk; Chetan K Potu; Ashley L Louie; Vivian Montes; Walter C Henderson; Kang Wang; Michael P Andre; Anthony E Samir; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2019-03-12       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.